Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
Conclusion: These results suggest that, at a willingness-to-pay threshold of $150,000 per QALY, nivolumab is a cost-effective option for therapy of SCCHN in the US.
PMID: 31928375 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Cancer & Oncology | Carcinoma | Economics | Health Management | Immunotherapy | Skin Cancer | Squamous Cell Carcinoma | Study | USA Health